Vanguard Group’s Kymera Therapeutics KYMR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $245M | Buy |
5,619,848
+388,456
| +7% | +$17M | ﹤0.01% | 1413 |
|
|
2025
Q1 | $143M | Buy |
5,231,392
+344,080
| +7% | +$9.42M | ﹤0.01% | 1633 |
|
|
2024
Q4 | $197M | Buy |
4,887,312
+133,546
| +3% | +$5.37M | ﹤0.01% | 1548 |
|
|
2024
Q3 | $225M | Sell |
4,753,766
-68,650
| -1% | -$3.25M | ﹤0.01% | 1485 |
|
|
2024
Q2 | $144M | Buy |
4,822,416
+55,366
| +1% | +$1.65M | ﹤0.01% | 1667 |
|
|
2024
Q1 | $192M | Buy |
4,767,050
+769,486
| +19% | +$30.9M | ﹤0.01% | 1548 |
|
|
2023
Q4 | $102M | Buy |
3,997,564
+72,351
| +2% | +$1.84M | ﹤0.01% | 1857 |
|
|
2023
Q3 | $54.6M | Buy |
3,925,213
+182,125
| +5% | +$2.53M | ﹤0.01% | 2088 |
|
|
2023
Q2 | $86.1M | Buy |
3,743,088
+9,163
| +0.2% | +$211K | ﹤0.01% | 1933 |
|
|
2023
Q1 | $111M | Buy |
3,733,925
+73,618
| +2% | +$2.18M | ﹤0.01% | 1783 |
|
|
2022
Q4 | $91.4M | Buy |
3,660,307
+797,130
| +28% | +$19.9M | ﹤0.01% | 1848 |
|
|
2022
Q3 | $62.3M | Sell |
2,863,177
-11,547
| -0.4% | -$251K | ﹤0.01% | 2075 |
|
|
2022
Q2 | $56.6M | Buy |
2,874,724
+36,999
| +1% | +$729K | ﹤0.01% | 2140 |
|
|
2022
Q1 | $120M | Sell |
2,837,725
-119,449
| -4% | -$5.06M | ﹤0.01% | 1840 |
|
|
2021
Q4 | $188M | Buy |
2,957,174
+55,600
| +2% | +$3.53M | ﹤0.01% | 1650 |
|
|
2021
Q3 | $170M | Buy |
2,901,574
+857,350
| +42% | +$50.4M | ﹤0.01% | 1697 |
|
|
2021
Q2 | $99.1M | Buy |
2,044,224
+311,879
| +18% | +$15.1M | ﹤0.01% | 2007 |
|
|
2021
Q1 | $67.3M | Buy |
1,732,345
+1,109,285
| +178% | +$43.1M | ﹤0.01% | 2147 |
|
|
2020
Q4 | $38.6M | Buy |
623,060
+157,010
| +34% | +$9.73M | ﹤0.01% | 2331 |
|
|
2020
Q3 | $15.1M | Buy |
+466,050
| New | +$15.1M | ﹤0.01% | 2587 |
|